Although afatinib is one of the standard treatments for patients with EGFR-mutated NSCLC, it is necessary to develop a combination therapy to overcome poor treatment outcomes, such as drug resistance and tumor recurrence [7]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.